Topigen Pharmaceutique Inc.
Records under this name other than patents Topigen Pharmaceutique Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 6 of 6 · Back to Topigen Pharmaceutique Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,745,420 | Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals Formerly held Lapsed on the fee record Ended Jun 29, 2022 · USPTO record | Lapsed on the fee record | Ended Jun 29, 2022 | USPTO record |
| US 6,822,087 | Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation Formerly held Term ended Term ended Jun 29, 2021 · USPTO record | Term ended | Term ended Jun 29, 2021 | USPTO record |
| US 7,629,324 | Antisense oligonucleotides for treating atopic diseases and neoplastic cell proliferation Term ended Term ended Oct 31, 2020 · USPTO record | Term ended | Term ended Oct 31, 2020 | USPTO record |
| US 7,825,236 | Oligonucleotide compositions and methods for treating disease including inflammatory conditions Lapsed on the fee record Ended Nov 2, 2018 · USPTO record | Lapsed on the fee record | Ended Nov 2, 2018 | USPTO record |
| US 7,579,455 | Oligonucleotide compositions and methods for treating disease including inflammatory conditions Lapsed on the fee record Ended Aug 25, 2017 · USPTO record | Lapsed on the fee record | Ended Aug 25, 2017 | USPTO record |
| US 8,173,796 | Oligonucleotide compositions and methods for treating disease including inflammatory conditions Lapsed on the fee record Ended May 8, 2016 · USPTO record | Lapsed on the fee record | Ended May 8, 2016 | USPTO record |